FDA grants Breakthrough Therapy Designation, Priority review and accepts NDA for Iberdomide in RRMM Patients; PDUFA Aug 2026 February 25, 2026
European Commission grants conditional marketing authorization for ANKTIVA + BCG in BCG-unresponsive NMIBC CIS, with or without papillary tumors February 25, 2026
Calquence + venetoclax approved in the US as oral, fixed-duration combination for 1L CLL patients February 25, 2026
